YHB Investment Advisors Inc. trimmed its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 0.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 33,334 shares of the company’s stock after selling 86 shares during the quarter. YHB Investment Advisors Inc.’s holdings in AbbVie were worth $6,583,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently modified their holdings of ABBV. Sovereign Financial Group Inc. boosted its position in shares of AbbVie by 18.6% in the first quarter. Sovereign Financial Group Inc. now owns 3,212 shares of the company’s stock valued at $585,000 after acquiring an additional 503 shares during the period. Revolve Wealth Partners LLC boosted its position in shares of AbbVie by 10.1% in the first quarter. Revolve Wealth Partners LLC now owns 3,083 shares of the company’s stock valued at $561,000 after acquiring an additional 282 shares during the period. DGS Capital Management LLC boosted its position in shares of AbbVie by 33.0% in the first quarter. DGS Capital Management LLC now owns 3,279 shares of the company’s stock valued at $597,000 after acquiring an additional 814 shares during the period. Wealthcare Advisory Partners LLC boosted its position in shares of AbbVie by 23.6% in the first quarter. Wealthcare Advisory Partners LLC now owns 42,837 shares of the company’s stock valued at $7,801,000 after acquiring an additional 8,184 shares during the period. Finally, Signet Financial Management LLC boosted its position in shares of AbbVie by 0.3% in the first quarter. Signet Financial Management LLC now owns 42,664 shares of the company’s stock valued at $7,769,000 after acquiring an additional 128 shares during the period. 70.23% of the stock is owned by institutional investors.
AbbVie Price Performance
AbbVie stock opened at $187.87 on Thursday. The business’s 50-day simple moving average is $194.22 and its 200 day simple moving average is $178.08. The stock has a market cap of $331.75 billion, a price-to-earnings ratio of 55.75, a P/E/G ratio of 2.66 and a beta of 0.63. AbbVie Inc. has a 12-month low of $135.85 and a 12-month high of $199.95. The company has a quick ratio of 0.71, a current ratio of 0.81 and a debt-to-equity ratio of 8.51.
AbbVie Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be issued a $1.55 dividend. This represents a $6.20 annualized dividend and a yield of 3.30%. The ex-dividend date is Tuesday, October 15th. AbbVie’s dividend payout ratio is 183.98%.
Insiders Place Their Bets
In other AbbVie news, Chairman Richard A. Gonzalez sold 66,500 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares in the company, valued at approximately $83,299,645.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.25% of the company’s stock.
Wall Street Analysts Forecast Growth
ABBV has been the subject of a number of recent research reports. Piper Sandler upped their target price on AbbVie from $196.00 to $209.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. Barclays upped their target price on AbbVie from $200.00 to $212.00 and gave the company an “overweight” rating in a research note on Monday, October 7th. Truist Financial upped their target price on AbbVie from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. TD Cowen upped their target price on AbbVie from $195.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, Bank of America upped their target price on AbbVie from $185.00 to $195.00 and gave the company a “neutral” rating in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus target price of $198.47.
Check Out Our Latest Stock Analysis on AbbVie
AbbVie Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More
- Five stocks we like better than AbbVie
- What Investors Need to Know About Upcoming IPOs
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Energy and Oil Stocks Explained
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.